Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data
JNCI: Journal of the National Cancer Institute · 01.03.2025 · 117 (3) · 476-485
DOI: 10.1093/jnci/djae260 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 17.10.2024. Verfasst von Lindsey Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIAAA NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
Data on the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on pancreatic cancer incidence are limited and inconsistent. Here we evaluate the association of GLP-1RAs, alone and in combinations, with incident pancreatic cancer risk in a real-world population, stratified by obesity and smoking status.
Methods
This retrospective cohort included patients with type 2 diabetes mellitus who were prescribed GLP-1RAs or other nonglucagon-like peptide-1 receptor agonist antidiabetes medications between January 2013 and March 2019 and had no prior diagnosis of pancreatic cancer. The incident (first-time) diagnosis of pancreatic cancer during a 5-year follow-up was compared between propensity-score matched cohorts of patients prescribed GLP-1RAs vs other nonglucagon-like peptide-1 receptor agonist antidiabetes medications. Subgroup analyses were performed in patients stratified by the status of obesity and tobacco use disorder. We also compared GLP-1RA combination therapies with monotherapies. Time-to-first-event analysis was performed using Cox proportional hazards and Kaplan–Meier survival analysis, with the hazard ratio and 95% confidence interval calculated.
Results
The study population comprised 1 636 056 eligible patients including 167 091 prescribed GLP-1RAs and 1 468 965 prescribed other antidiabetes medications. GLP-1RAs were associated with a statistically significant decreased risk for pancreatic cancer incidence compared with each of 6 nonglucagon-like peptide-1 receptor agonist antidiabetes medications with hazard ratios ranging from 0.42 to 0.82. The reduction was greater in patients with obesity and tobacco use disorder than in those without. GLP-1RA combination therapies were associated with lower pancreatic cancer risk compared with monotherapies.
Conclusions
GLP-1RAs were associated with reduced pancreatic cancer incidence in patients with type 2 diabetes mellitus. Further studies and trials are needed to explore mechanisms and confirm causal effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.
- Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.
- Department of Family Medicine, University of Virginia, Charlottesville, VA 22903, United States.
- University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, VA 22908, United States.
- Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, OH 44109, United States.
- Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.
ORCID-Profile: Li Li, David C Kaelber, Rong Xu
Förderung
- NIA NIH HHS
- NIAAA NIH HHS
- NCATS NIH HHS
- NCI NIH HHS
- Landon Foundation-AACR
- NICHD NIH HHS
- National Institute of Health
- National Cancer Institute Case Comprehensive Cancer Center
Zitieren
APA
Wang, L., Wang, Q., Li, L., Kaelber, D. C., & Xu, R. (2025). Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data. JNCI: Journal of the National Cancer Institute, 117(3), 476-485. https://doi.org/10.1093/jnci/djae260
Vancouver
Wang L, Wang Q, Li L, Kaelber DC, Xu R. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data. JNCI: Journal of the National Cancer Institute. 2025;117(3):476-485. doi:10.1093/jnci/djae260
BibTeX
@article{Wang2025,
author = {Wang, Lindsey and Wang, QuanQiu and Li, Li and Kaelber, David C and Xu, Rong},
title = {Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
volume = {117},
number = {3},
pages = {476--485},
doi = {10.1093/jnci/djae260}
}
EUVIMED